Disease Landscape and Forecast Insights

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key soft tissue sarcoma patient populations covering 171 countries and more…

The malignant melanoma market in Europe has become crowded. Small-molecule targeted therapies such as Novartis’s Tafinlar and Mekinist, monoclonal antibodies including Merck & Co.’s Keytruda…

Essential thrombocythemia (ET) is a rare chronic myeloproliferative disease characterized by the overproduction of platelets. While the etiology of ET is not fully understood, a genetic mutation…

Clarivate Epidemiology’s coverage of liposarcoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA), Vectibix (Amgen), Zaltrap (Regeneron/Sanofi), Cyramza (Eli Lilly), Stivarga (Bayer HealthCare), and Lonsurf (Servier)—are…

The large size of the HER2-positive breast cancer market in Europe, driven by high incidence and long treatment duration with expensive agents, is of great commercial interest to drug developers…

Chronic infection with hepatitis C virus (HCV) is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The 2013-2015 EMA…

Chronic infection with hepatitis C virus (HCV) is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The 2013-2015 FDA…